Literature DB >> 3345594

Splanchnic artery occlusion shock in the rat: effects of the calcium entry blockers nimodipine and verapamil.

R Sturniolo1, D Altavilla, M C Berlinghieri, F Squadrito, A P Caputi.   

Abstract

Splanchnic artery occlusion (SAO) shock made by clamping splanchnic arteries for 45 min was performed in female rats infused for 30 min with vehicle, nimodipine, and verapamil before, during, or after SAO. Survival time, macrophage phagocytosis and killing, and white cell count were evaluated in conscious rats. Shocked animals pretreated with vehicle exhibited 24.6 +/- 0.9% phagocytic activity, 5.1 +/- 0.7% killing activity, and survived 177 +/- 1.7 min. Leukopenia was also present. Sham animals survived more than 300 min, and showed the following values: phagocytosis = 52.8 +/- 0.6%, killing = 18.8 +/- 0.6%. Pretreatment with nimodipine (1 microgram/kg/min x 30 min, intravenously [IV]) before SAO significantly prolonged survival time (274 +/- 4.7 min) and improved phagocytosis (38.1 +/- 0.6%) and killing (16.1 +/- 1.1%), but did not change leukopenia. Lower doses of nimodipine (0.25 and 0.5 microgram/kg/min x 30 min, IV), and all the doses of verapamil (100 and 200 micrograms/kg/min x 30 min, IV), when infused before SAO, were ineffective. Neither nimodipine nor verapamil, when infused for 30 min either during or immediately after SAO, were able to influence survival, macrophage functions, or white cell count. Moreover, nimodipine (5, 10, and 25 microM), when added "in vitro" to macrophages collected from SAO-shocked rats, significantly enhanced their phagocytic activity, while verapamil (100 and 200 microM) did not change it. Finally, in anaesthetized rats nimodipine pretreatment had a beneficial effect on the cardiovascular changes occurring during SAO shock. These data suggest that nimodipine has a beneficial effect in SAO-shocked rats only when given before SAO.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3345594

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  6 in total

1.  Monocytes and lymphocytes as active participants in the pathogenesis of experimental shock.

Authors:  D Altavilla; F Squadrito; L Ammendolia; G Squadrito; G M Campo; P Canale; M Ioculano; C Musolino; A Alonci; A Sardella; G Urna; A Saitta; A P Caputi
Journal:  Inflamm Res       Date:  1996-08       Impact factor: 4.575

2.  TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock.

Authors:  P Canale; F Squadrito; D Altavilla; M Ioculano; B Zingarelli; G M Campo; G Urna; A Sardella; G Squadrito; A P Caputi
Journal:  Agents Actions       Date:  1994-10

3.  Contribution of intercellular adhesion molecule 1 (ICAM-1) to the pathogenesis of splanchnic artery occlusion shock in the rat.

Authors:  F Squadrito; D Altavilla; P Canale; M P Ioculano; G M Campo; L Ammendolia; G Squadrito; A Saitta; G Calapai; A P Caputi
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

4.  Improved survival and reversal of endothelial dysfunction by the 21-aminosteroid, U-74389G in splanchnic ischaemia-reperfusion injury in the rat.

Authors:  F Squadrito; D Altavilla; L Ammendolia; G Squadrito; G M Campo; A Sperandeo; P Canale; M Ioculano; A Saitta; A P Caputi
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

5.  Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock.

Authors:  F Squadrito; D Altavilla; P Canale; M Ioculano; G M Campo; L Ammendolia; M Ferlito; B Zingarelli; G Squadrito; A Saitta
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

6.  Nimodipine Exerts Time-Dependent Neuroprotective Effect after Excitotoxical Damage in Organotypic Slice Cultures.

Authors:  Urszula Hohmann; Chalid Ghadban; Tim Hohmann; Joshua Kleine; Miriam Schmidt; Christian Scheller; Christian Strauss; Faramarz Dehghani
Journal:  Int J Mol Sci       Date:  2022-03-19       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.